Market capitalization | €1.82b |
Enterprise Value | €1.88b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 27.48 |
EV/Sales (TTM) EV/Sales | 2.03 |
P/S ratio (TTM) P/S ratio | 1.96 |
P/B ratio (TTM) P/B ratio | 1.22 |
Dividend yield | 2.16% |
Last dividend (FY24) | €0.18 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
10 Analysts have issued a Almirall forecast:
10 Analysts have issued a Almirall forecast:
Jun '24 |
+/-
%
|
||
Revenue | 926 926 |
4%
4%
|
|
Gross Profit | 363 363 |
2%
2%
|
|
EBITDA | 169 169 |
5%
5%
|
EBIT (Operating Income) EBIT | 39 39 |
29%
29%
|
Net Profit | -35 -35 |
218%
218%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Almirall SA is a global biopharmaceutical company, which is focused on skin health. It engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The firm operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not Allocated Assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological, and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.
Head office | Spain |
CEO | Carlos Piqué |
Employees | 1,904 |
Founded | 1995 |
Website | www.almirall.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.